10rx vs NewSelf
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
NewSelf
Best for: semaglutide at $100/month, 47% under the register median
Visit NewSelf →Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, 10rx opens cheaper — $99.67/mo against $100, and NewSelf finishes ahead, 8.6 to 8.1. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
10rx
Compounded; GLP-1 options as low as under $100/mo
Compounded GLP-1 + GIP
NewSelf
All dosages same price
All dosages same price
What’s included
10rx
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
NewSelf
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
10rx
8.1/10
NewSelf
8.6/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | 10rx | NewSelf |
|---|---|---|
| Starting Price | ✓$99.67/mo | $100/mo |
| Features | ✓8 features | 6 features |
| States Available | Not disclosed | 49 |
| Compounded | — | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | ✓None | 1 warning |
About 10rx
10rx sets flat monthly rates on compounded GLP-1: semaglutide at $99.67, tirzepatide at $149.67, with NAD+ and sermorelin sold separately for energy and recovery. A free health quiz online reaches a board-certified telehealth doctor, who reads your history before writing anything, and licensed pharmacy partners handle discreet delivery. The company states it reaches every one of the 50 states. What it does not state is its operating company, its pharmacies, or any terms page.
Read our full 10rx review →About NewSelf
NewSelf sells compounded semaglutide+ with B12 and glycine from $99.97/mo and compounded tirzepatide+ with B6 and glycine from $144.49/mo. It is LegitScript certified and available in 48 states plus Puerto Rico, using 503A licensed pharmacies with third-party testing.
Read our full NewSelf review →Pros & Cons
10rx
What we like
- Semaglutide at $99.67 a month, 47% below the $189 median for the same drug and form across this register
- Tirzepatide at $149.67 a month, 44% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
NewSelf
What we like
- Semaglutide at $100 a month, 47% below the $189 median for the same drug and form across this register
- Tirzepatide at $144 a month, 46% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- Coverage is published for 49 states
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
NewSelf takes it, 8.6 against 8.1, and it is especially strong on semaglutide at $100/month, 47% under the register median. 10rx is no weak second and may fit you better on semaglutide at $99.67/month, 47% under the register median.
Choose 10rx if…
You want semaglutide at $99.67/month, 47% under the register median and an opening price near $99.67 a month.
Choose NewSelf if…
You want semaglutide at $100/month, 47% under the register median and an opening price near $100 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Telos Rx
Starting below a standard dose, with microdose tiers
From $49/mo
Get started →MyDrHank
An oral route if you will not self-inject
From $25/mo
Get started →SkinnyRx
Starting below a standard dose, with microdose tiers
From $149.25/mo
Get started →10rx vs NewSelf: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring 10rx and NewSelf head-to-heads in the same category.
- 10rx vs Trimi Health
- 10rx vs Embody
- 10rx vs He & She MD
- NewSelf vs Lean Meds
- NewSelf vs NextMeds
- NewSelf vs bmiMD
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.